Details for New Drug Application (NDA): 214047
NDA 214047 describes THYQUIDITY, which is a drug marketed by Stevens J and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the THYQUIDITY profile page.
The generic ingredient in THYQUIDITY is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
The generic ingredient in THYQUIDITY is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 214047
| Tradename: | THYQUIDITY |
| Applicant: | Stevens J |
| Ingredient: | levothyroxine sodium |
| Patents: | 1 |
Suppliers and Packaging for NDA: 214047
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| THYQUIDITY | levothyroxine sodium | SOLUTION;ORAL | 214047 | NDA | Oliva Therapeutics, LLC | 82685-360 | 82685-360-01 | 1 BOTTLE, GLASS in 1 CARTON (82685-360-01) / 100 mL in 1 BOTTLE, GLASS |
| THYQUIDITY | levothyroxine sodium | SOLUTION;ORAL | 214047 | NDA | Oliva Therapeutics, LLC | 82685-360 | 82685-360-02 | 2 BOTTLE, GLASS in 1 CARTON (82685-360-02) / 100 mL in 1 BOTTLE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 100MCG/5ML | ||||
| Approval Date: | Nov 30, 2020 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Aug 6, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
